The plant extract of Pao pereira potentiates carboplatin effects against ovarian cancer

Pharmaceutical Biology

Volumn 52, Issue 1, 2014, Pages 36-43

  Yu, Jun ^a   Chen, Qi ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Anticancer; Combination therapy; Natural product; Synergy

Indexed keywords

ALKALOID; ANTINEOPLASTIC AGENT; BETA CARBOLINE; CARBOPLATIN; PAO PEREIRA EXTRACT; PLANT EXTRACT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOCYNACEAE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; COLONY FORMING CELL; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; EPITHELIUM CELL; FEMALE; FLOW CYTOMETRY; IC 50; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PAO PEREIRA;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOCYNACEAE; APOPTOSIS; CARBOPLATIN; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; HUMANS; INJECTIONS, INTRAPERITONEAL; MEDICINE, TRADITIONAL; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PLANT EXTRACTS; SOUTH AMERICA; TIME FACTORS;

EID: 84890532625     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2013.808232     Document Type: Article

References (33)

1. Bast Jr RC. (2011). Molecular approaches to personalizing management of ovarian cancer. Ann Oncol 22:viii5-15
2. Beljanski M, Beljanski MS. (1982). Selective inhibition of in vitro synthesis of cancer DNA by alkaloids of beta-carboline class. Exp Cell Biol 50:79-87
3. Beljanski M, Beljanski MS. (1986). Three alkaloids as selective destroyers of cancer cells in mice. Synergy with classic anticancer drugs. Oncology 43:198-203
4. Beljanski M, Crochet S, Beljanski MS. (1993). PB-100: A potent and selective inhibitor of human BCNU resistant glioblastoma cell multiplication. Anticancer Res 13:2301-8
5. Bell-McGuinn KM, Matthews CM, Ho SN, et al. (2011). A phase II, single-arm study of the anti-alpha5beta1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol 121: 273-9
6. Bellati F, Napoletano C, Ruscito I, et al. (2010). Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review. Invest New Drugs 28: 887-94
7. Beller U, Quinn MA, Benedet JL, et al. (2006). Carcinoma of the vulva. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 95:S7-27
8. Bemis DL, Capodice JL, Desai M, et al. (2009). Beta-carboline alkaloid-enriched extract from the amazonian rain forest tree pao pereira suppresses prostate cancer cells. J Soc Integr Oncol 7: 59-65
9. Buys SS, Partridge E, Greene MH, et al. (2005). Ovarian cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: Findings from the initial screen of a randomized trial. Am J Obstet Gynecol 193:1630-9
10. Cao R, Chen Q, Hou XR, et al. (2004). Synthesis, acute toxicities, and antitumor effects of novel 9-substituted beta-carboline derivatives. Bioorg Med Chem 12:4613-23
11. Chao MP, Majeti R, Weissman IL. (2012). Programmed cell removal: A new obstacle in the road to developing cancer. Nat Rev Cancer 12: 58-67
12. Chen F. (2012). JNK-induced apoptosis, compensatory growth, and cancer stem cells. Cancer Res 72:379-86
13. Chen H, Hardy TM, Tollefsbol TO. (2011). Epigenomics of ovarian cancer and its chemoprevention. Front Genet 2:67
14. Chen Q, Chao RH, Chen HS, et al. (2005). Antitumor and neurotoxic effects of novel harmine derivatives and structure-activity relationship analysis. Int J Cancer 114:675-82
15. Cole SP. (1986). Rapid chemosensitivity testing of human lung tumor cells using the MTT assay. Cancer Chemother Pharmacol 17: 259-63
16. Denizot F, Lang R. (1986). Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 89: 271-7
17. Donaldson KL, Goolsby GL, Wahl AF. (1994). Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int J Cancer 57:847-55
18. du Bois A, Luck HJ, Merer W, et al. (1997). Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: An interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group. Semin Oncol 24:S15-44-52
19. Eagle H, Foley GE, Koprowski H, et al. (1970). Growth characteristics of virus-transformed cells. Maximum population density, inhibition by normal cells, serum requirement, growth in soft agar, and xenogeneic transplantability. J Exp Med 131:863-79
20. Fu S, Hennessy BT, Ng CS, et al. (2012). Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol 126: 47-53
21. Goldberg JM, Piver MS, Hempling RE, Recio FO. (1996). Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer. Gynecol Oncol 63:312-17
22. Imai S, Kiyozuka Y, Maeda H, et al. (1990). Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen. Oncology 47:177-84
23. Mbeunkui F, Grace MH, Lategan C, et al. (2012). In vitro antiplasmodial activity of indole alkaloids from the stem bark of Geissospermum vellosii. J Ethnopharmacol 139:471-7
24. McGuire WP, Hoskins WJ, Brady MF, et al. (1996). Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: A phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 23:40-7
25. Milross CG, Peters LJ, Hunter NR, et al. (1995). Sequence-dependent antitumor activity of paclitaxel (taxol) and cisplatin in vivo. Int J Cancer 62:599-604
26. Monk BJ, Coleman RL. (2009). Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: From platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. Int J Gynecol Cancer 19:S63-7
27. Ozols RF. (1995). Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. Semin Oncol 22:1-6
28. Puiseux F, LeHir A, Goutarel R, et al. (1959). On the alkaloids of ''paopereirá', Geissospermum laeve (Vellozo) Baillon. Note III. Geissoschizoline, apogeissoschizine and geissospermine. Ann Pharm Fr 17:626-33
29. Pujade-Lauraine E, Guastalla JP, Weber B, et al. (1997). Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: A multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study. Semin Oncol 24: S15-30-35
30. Reina M, Ruiz-Mesia W, Lopez-Rodriguez M, et al. (2012). Indole alkaloids from Geissospermum reticulatum. J Nat Prod 75:928-34
31. Steele JC, Veitch NC, Kite GC, et al. (2002). Indole and betacarboline alkaloids from Geissospermum sericeum. J Nat Prod 65: 85-8
32. Weroha SJ, Oberg AL, Ziegler KL, et al. (2011). Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/ resistant ovarian and primary peritoneal carcinoma. Gynecol Oncol 122:116-20
33. Zeng G, Cai S, Liu Y, Wu GJ. (2012). METCAM/MUC18 augments migration, invasion, and tumorigenicity of human breast cancer SK-BR-3 cells. Gene 492:229-38